4.4 Article

Guidelines for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults

期刊

CEPHALALGIA
卷 40, 期 10, 页码 1026-1044

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/0333102420941839

关键词

-

资金

  1. Allergan
  2. electroCore
  3. German Research Council (DFG)
  4. German Ministry of Education and Research (BMBF)
  5. European Union
  6. NIH [2PO1 AG003949, 5U10 NS077308, R21 AG056920, 1RF1 AG057531, RF1 AG054548, 1RO1 AG048642, R56 AG057548, U01062370, RO1 AG060933, RO1 AG062622, 1UG3FD006795, 1U24NS113847, K23 NS09610, K23AG049466, K23 NS107643]
  7. Migraine Research Foundation
  8. National Headache Foundation

向作者/读者索取更多资源

Clinical trials are a key component of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of theGuidelines for Controlled Trials of Drugs in Migraine. Advances in drugs, devices, and biologicals, as well as novel trial designs, have prompted several updates over the nearly 30 years since, including most recently theGuidelines for controlled trials of preventive treatment of chronic migraine(2018), theGuidelines for controlled trials of acute treatment of migraine attacks in adults(2019), andGuidelines for controlled trials of preventive treatment of migraine in children and adolescents(2019). The present update incorporates findings from new research and is intended to optimize the design of controlled trials of preventive pharmacological treatment of episodic migraine in adults. A guideline for clinical trials with devices will be published separately.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据